clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
Published 8 months ago • 137 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:25
outcomes & healthcare utilization cost of patients with cll refractory to btk and bcl-2 inhibitors
-
1:20
improving outcomes of non-covalent btki treatment
-
1:31
clinical outcomes are poor for cll patients treated with venetoclax post-btki exposure
-
1:57
addressing cardiovascular aes associated with btki treatment in patients with cll
-
1:52
novel options for patients with cll who relapse after treatment with btk inhibitors and venetoclax
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
1:46
managing the side effects associated with btki treatment for cll
-
![how do ms medications work? decoding immunosuppression [part 2]](https://i.ytimg.com/vi/AL6yF9kBwlM/mqdefault.jpg)
11:57
how do ms medications work? decoding immunosuppression [part 2]
-
7:35
what is chronic lymphocytic leukaemia (cll) / small lymphocytic lymphoma (sll)?
-
3:30
treatment options for young, newly diagnosed & low-risk patients with cll
-
4:10
treating cll after intolerance or progression on btki
-
5:45
treatment effectiveness of venetoclax-based therapy after btki exposure in cll/sll
-
1:19
outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
0:59
the impact of age and comorbidities on the outcomes of patients with cll treated with btk inhibitors
-
2:19
long-term management of cll for improved outcomes
-
1:03
ecog-e1910 study: clinical benefit of early blinatumomab incorporation in all
-
1:24
sequencing of btk inhibitors in cll
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
1:56
approaching treatment selection and sequencing with the recent influx of btk inhibitors in cll
-
4:57
sequencing of targeted therapies for cll